D'Souza Donna L, Ragulojan Ranjan, Guo Chunxiao, Dale Connie M, Jones Christopher J, Talaie Reza
Division of Interventional Radiology, Department of Radiology, University of Minnesota, Minneapolis, Minnesota.
Semin Intervent Radiol. 2024 Jan 24;40(6):491-496. doi: 10.1055/s-0043-1777845. eCollection 2023 Dec.
Cryoablation is commonly used in the kidney, lung, breast, and soft tissue, but is an uncommon choice in the liver where radiofrequency ablation (RFA) and microwave ablation (MWA) predominate. This is in part for historical reasons due to serious complications that occurred with open hepatic cryoablation using early technology. More current technology combined with image-guided percutaneous approaches has ameliorated these issues and allowed cryoablation to become a safe and effective thermal ablation modality for treating liver tumors. Cryoablation has several advantages over RFA and MWA including the ability to visualize the ice ball, minimal procedural pain, and strong immunomodulatory effects. This article will review the current literature on cryoablation of primary and secondary liver tumors, with a focus on efficacy, safety, and immunogenic potential. Clinical scenarios when it may be more beneficial to use cryoablation over heat-based ablation in the liver, as well as directions for future research, will also be discussed.
冷冻消融常用于肾脏、肺部、乳腺和软组织,但在肝脏中是一种不常见的选择,在肝脏中射频消融(RFA)和微波消融(MWA)更为常用。部分原因是历史原因,早期技术的开放性肝脏冷冻消融出现了严重并发症。更新的技术与图像引导的经皮方法相结合,改善了这些问题,并使冷冻消融成为治疗肝脏肿瘤的一种安全有效的热消融方式。与RFA和MWA相比,冷冻消融有几个优点,包括能够可视化冰球、手术疼痛最小以及强大的免疫调节作用。本文将综述关于原发性和继发性肝脏肿瘤冷冻消融的当前文献,重点关注疗效、安全性和免疫原性潜力。还将讨论在肝脏中使用冷冻消融比热消融更有益的临床情况,以及未来的研究方向。